How to buy Anchiano Therapeutics stock

Anchiano Therapeutics Ltd is a biotechnology business based in the US. Anchiano Therapeutics shares (ANCN) are listed on the NASDAQ and all prices are listed in US Dollars. Anchiano Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Anchiano Therapeutics stock price (NASDAQ: ANCN)

Use our graph to track the performance of ANCN stocks over time.

Anchiano Therapeutics shares at a glance

• Key figures

Information last updated 2021-06-13.

52-week range	$16.80 - $94.40
50-day moving average	$61.36
200-day moving average	$34.74
Wall St. target price	$1.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.21

Buy Anchiano Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Anchiano Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anchiano Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-52.84%
Return on equity TTM	-125.6%
Profit margin	0%
Book value	$7.71
Market capitalisation	$34.9 million

TTM: trailing 12 months

Shorting Anchiano Therapeutics shares

There are currently 65,165 Anchiano Therapeutics shares held short by investors – that's known as Anchiano Therapeutics's "short interest". This figure is 65.7% down from 190,175 last month.

There are a few different ways that this level of interest in shorting Anchiano Therapeutics shares can be evaluated.

Anchiano Therapeutics's "short interest ratio" (SIR)

Anchiano Therapeutics's "short interest ratio" (SIR) is the quantity of Anchiano Therapeutics shares currently shorted divided by the average quantity of Anchiano Therapeutics shares traded daily (recently around 3.3 million). Anchiano Therapeutics's SIR currently stands at 0.02. In other words for every 100,000 Anchiano Therapeutics shares traded daily on the market, roughly 20 shares are currently held short.

However Anchiano Therapeutics's short interest can also be evaluated against the total number of Anchiano Therapeutics shares, or, against the total number of tradable Anchiano Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anchiano Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Anchiano Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Anchiano Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anchiano Therapeutics.

Find out more about how you can short Anchiano Therapeutics stock.

Anchiano Therapeutics share dividends

We're not expecting Anchiano Therapeutics to pay a dividend over the next 12 months.

Anchiano Therapeutics share price volatility

Over the last 12 months, Anchiano Therapeutics's shares have ranged in value from as little as $16.8 up to $94.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anchiano Therapeutics's is 0.9598. This would suggest that Anchiano Therapeutics's shares are less volatile than average (for this exchange).

Anchiano Therapeutics overview

Anchiano Therapeutics Ltd. , a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd.

Frequently asked questions

What percentage of Anchiano Therapeutics is owned by insiders or institutions?
Currently 3.817% of Anchiano Therapeutics shares are held by insiders and 3.455% by institutions. How many people work for Anchiano Therapeutics?
Latest data suggests 3 work at Anchiano Therapeutics. When does the fiscal year end for Anchiano Therapeutics?
Anchiano Therapeutics's fiscal year ends in December. Where is Anchiano Therapeutics based?
Anchiano Therapeutics's address is: One Kendall Square, Cambridge, MA, United States, 02139 What is Anchiano Therapeutics's ISIN number?
Anchiano Therapeutics's international securities identification number is: US03280X1028 What is Anchiano Therapeutics's CUSIP number?
Anchiano Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03280X102